Update on the pathogenesis of diabetic neuropathy

Current Diabetes Reports

Volumn 3, Issue 6, 2003, Pages 439-445

  Obrosova, Irina G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; CELIKALIM; CHELERYTHRINE; CREMOPHOR; FRUCTOSAMINE; GLUTATHIONE; IDITOL DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NEUROTROPHIC FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PENTOSIDINE; PRAZOSIN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PYRIDOXAMINE; REACTIVE OXYGEN METABOLITE; RUBOXISTAURIN; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

APOPTOSIS; BLOOD FLOW; DIABETES MELLITUS; DIABETIC NEUROPATHY; ENZYME ACTIVATION; ENZYME ACTIVITY; FOOT AMPUTATION; GLYCATION; HUMAN; MOTOR NERVE CONDUCTION; NEUROCHEMISTRY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SENSORY NERVE CONDUCTION; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES;

EID: 3142761609     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-003-0005-1     Document Type: Review

References (56)

1. Boulton AJ: Treatments for diabetic neuropathy. Curr Diabetes Rep 2001, 1:127-132.
2. Cameron NE, Eaton SE, Cotter MA, Tesfaye S: Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001, 44:1973-1988.
3. Obrosova IG, Van Huysen C, Fathallah L, et al.: An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 2002, 16:123-125.
4. Cameron NE, Cotter MA, Jack AM, et al.: Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats. Diabetologia 1999, 42:1120-1130.
5. Stevens MJ, Obrosova I, Cao X, et al.: Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000, 49:1006-1105.
6. Sima AA, Sugimoto K: Experimental diabetic neuropathy: an update. Diabetologia 1999, 42:773-788.
7. Williamson JR, Chang K, Fringes M, et al.: Hyperglycemia pseudohypoxia and diabetic complications. Diabetes 1993, 42:801-813.
8. Kuruvilla R, Eichberg J: Depletion of phospholipid arachidonoyl-containing molecular species in a human Schwann cell line grown in elevated glucose and their restoration by an aldose reductase inhibitor. J Neurochem 1998, 71:775-783.
9. Tomlinson DR, Fernyhough P, Diemel LT: Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes 1997, 46(suppl 2):S43-S49.
10. Calcutt NA, Campana WM, Eskeland NL, et al.: Prosaposin gene expression and the efficacy of a prosaposin-derived peptide in preventing structural and functional disorders of peripheral nerve in diabetic rats. J Neuropathol Exp Neurol 1999, 58:628-636.
11. Russell JW, Sullivan KA, Windebank AJ, et al.: Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis 1999, 6:347-363.
12. Schmeichel AM, Schmelzer JD, Low PA: Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 2003, 52:165-171.
13. Obrosova IG, Van Huysen C, Fathallah L, et al.: Evaluation of alpha(1)-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 2000, 14:1548-1558.
14. Hohman TC, Cotter MA, Cameron NE: ATP-sensitive K(+) channel effects on nerve function, Na(+), K(+) ATPase, and glutathione in diabetic rats. Eur J Pharmacol 2000, 397:335-341.
15. Cameron NE, Cotter MA: Effects of an extracellular metal chelator on neurovascular function in diabetic rats. Diabetologia 2001, 44:621-628.
16. Coppey LJ, Gellett JS, Davidson EP, et al.: Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001, 50:1927-1937.
17. Chidlow G, Schmidt KG, Wood JP, et al.: Alpha-lipoic acid protects the retina against ischemia-reperfusion. Neuropharmacology 2002, 43:1015-1025.
18. Calcutt NA, Allendoerfer K, Mizisin AP, et al.: Therapeutic efficacy of sonic hedgehog protein in experimental diabetic neuropathy. J Clin Invest 2003, 111:507-514.
19. Garcia Soriano F, Virag L, Jagtap P, et al.: Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001, 7:108-113.
20. Obrosova IG, Fathallah L, Lang HJ, Greene DA: Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: a prevention study. Diabetologia 1999, 42:1187-1194.
21. Oates PJ: Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 2002, 50:325-392.
22. Yagihashi S, Yamagishi SI, Wada R, et al.: Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitors. Brain 2001, 124:2448-2458.
23. Song Z, Fu DTW, Chan YS, et al.: Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress. Mol Cell Neurosci 2003, 23:638-647.
24. Coppey LJ, Gellett JS, Davidson EP, et al.: Effect of treating streptozotocin-induced diabetic rats with sorbinil, myo-inositol or aminoguanidine on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Int J Exp Diabetes Res 2002, 3:21-36.
25. Kato N, Mizuno K, Makino M, et al.: Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats. Diabetes Res Clin Pract 2000, 50:77-85.
26. Hotta N, Toyota T, Matsuoka K, et al.: Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy. SNK-860 Diabetic Neuropathy Study Group. Diabetes Care 2001, 24:1776-1782.
27. Greene DA, Arezzo JC, Brown MB: Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999, 53:580-591.
28. Ng TF, Lee FK, Song ZT, et al.: Effects of sorbitol dehydrogenase deficiency on nerve conduction in experimental diabetic mice. Diabetes 1998, 47:961-966.
29. Schmidt RE, Dorsey DA, Beaudet LN, et al.: Inhibition of a sorbitol dehydrogenase exacerbates autonomic neuropathy in rats with streptozotocin-induced diabetes. J Neuropathol Exp Neurol 2001, 60:1153-1169.
30. Thornalley PJ: Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 2002, 50:37-57.
31. Dickinson PJ, Carrington AL, Frost GS, Boulton AJ: Neurovascular disease, antioxidants and glycation in diabetes. Diabetes Metab Res Rev 2002, 18:260-272.
32. Wada R, Nishizawa Y, Yagihashi N, et al.: Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 2001, 31:513-520.
33. Amano S, Kaji Y, Oshika T, et al.: Advanced glycation end products in human optic nerve head. Br J Ophthalmol 2001, 85:52-55.
34. Eichberg J: Protein kinase C changes in diabetes: is the concept relevant to neuropathy? Int Rev Neurobiol 2002, 50:61-82.
35. Jack AM, Cameron NE, Cotter MA: Effects of the diacylglycerol complexing agent, cremophor, on nerve-conduction velocity and perfusion in diabetic rats. J Diabetes Complications 1999, 13:2-9.
36. Nakamura J, Kato K, Hamada Y, et al.: A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999, 48:2090-2095.
37. Coppey LJ, Gellett JS, Davidson EP, Yorek MA: Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation. Free Radic Res 2003, 37:33-40.
38. Obrosova IG, Fathallah L, Stevens MJ: Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp Neurol 2001, 172:211-219.
39. Coppey LJ, Gellett JS, Davidson EP, et al.: Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br J Pharmacol 2001, 134:21-29.
40. Hounsom L, Corder R, Patel J, Tomlinson DR: Oxidative stress participates in the breakdown of neuronal phenotype in experimental diabetic neuropathy. Diabetologia 2001, 44:424-428.
41. Nishikawa T, Edelstein D, Du XL, et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
42. Cotter MA, Cameron NE: Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats. Life Sci 2003, 73:1813-1824.
43. Gupta S, Chough E, Daley J, et al.: Hyperglycemia increases endothelial superoxide that impairs smooth muscle cell Na+-K+-ATPase activity. Am J Physiol 2002, 282:C560-C566.
44. Obrosova IG, Minchenko AG, Vasupuram R, et al.: Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 2003, 52:864-871.
45. El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB: High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 2003, 44:3135-3143.
46. Stern DM, Yan SD, Yan SF, Schmidt AM: Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002, 1:1-15.
47. Abiko T, Abiko A, Clermont AC, et al.: Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes 2003, 52:829-837.
48. Nakamura N, Obayashi H, Fujii M, et al.: Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products. Free Radic Biol Med 2000, 29:17-25.
49. Srinivasan S, Stevens M, Wiley JW: Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. Diabetes 2000, 49:1932-1938.
50. Sango K, Horie H, Saito H, et al.: Diabetes is not a potent inducer of neuronal cell death in mouse sensory ganglia, but it enhances neurite regeneration in vitro. Life Sci 2002, 71:2351-2368.
51. Russell JW, Golovoy D, Vincent AM, et al.: High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J 2002, 16:1738-1748.
52. Purves T, Middlemas A, Agthong S, et al.: A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J 2001, 15:2508-2514.
53. Fernyhough P, Gallagher A, Averill SA, et al.: Aberrant neurofilament phosphorylation in sensory neurons of rats with diabetic neuropathy. Diabetes 1999, 48:881-889.
54. Agthong S, Tomlinson DR: Inhibition of p38 MAP kinase corrects biochemical and neurological deficits in experimental diabetic neuropathy. Ann N Y Acad Sci 2002, 973:359-362.
55. Minchenko AG, Stevens MJ, White L, et al.: Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 2003, 17:1514-1516.
56. Ha HC, Hester LD, Snyder SH: Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc Natl Acad Sci U S A 2002, 99:3270-3275.